NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cidara Therapeutics, Inc. (CDTX) Stock Analysis

Cidara Therapeutics, Inc. (CDTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CDTX

$221.38

$0.00 (0.00%)

Last trade January 8, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDTX with… →

CDTX Key Statistics

As of Jan 8, 2026
Trading
Open
$221.38
Previous Close
$221.38
52-Week Range
15.22–221.42
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$6.96B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−11.20
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+789.79%
Dividend and dates
Avg Volume
1.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CDTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.22%
2025+721.76%
2024 (partial year)+19.41%

As of January 8, 2026.

CDTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricCDTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Cidara Therapeutics, Inc. (CDTX) at $6.96B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 38.

Over the past 52 weeks the price has ranged from $15.22 to $221.42. The most recent close on file for CDTX is $221.38, dated January 8, 2026. The close was unchanged from the previous session. The latest close sits 1,354.53% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $0.00. The reported profit margin is 0%. Trailing earnings per share are −11.2.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +789.79%. Beta against the wider market is reported at 1.53. Daily returns over the trailing 1 year annualize to a volatility of 168.69%.

Growth & Income

The record shows no dividend for CDTX.

The record holds one complete calendar year, 2025, which returned +721.76%. 2026 is still running; the price is +0.22% year to date.

Peer Comparison

Cidara Therapeutics, Inc. (CDTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cidara Therapeutics, Inc. CDTX $6.96B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cidara Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of January 8, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Visit website →